Gender in cardiac resynchronisation therapy
- PMID: 30680077
- PMCID: PMC6335983
- DOI: 10.15171/jcvtr.2018.34
Gender in cardiac resynchronisation therapy
Abstract
Introduction: Gender differences in cardiac resynchronisation therapy (CRT) response are not clear enough. This study aimed to assess gender influence on systemic inflammation, neurohormonal activation, fibrosis in patients with congestive heart failure (CHF) and CRT. Methods: We compared group I (61 men) and group II (16 women) of patients undergoing CRT. Plasma levels of Nt-proBNP, interleukin (IL)-1β, IL-6, IL-10, tumor necrosis factor alpha (TNF-α), C-reactive protein, galectin-3 (Gal-3), metalloproteinase-9 (MMP-9), tissue inhibitors of metalloproteinase 1 and 4 (TIMP-1, TIMP-4), ratio MMP-9/TIMP-1, MMP-9/TIMP-4 were measured. According to dynamics of left ventricular end-systolic volume patients were classified into non-responders, responders, super-responders. Results: Women more likely had left bundle branch block (81.3 vs 47.5%, P = 0.016), were more super-responders (66.7 vs 30.5%). Both groups showed decrease of IL-6 (P < 0.05), TNF-α (P < 0.001; P < 0.05), NT-proBNP (P = 0.001; P < 0.05), Gal-3 (P < 0.05). In women there was decrease of IL-6 by 44.4 vs 23.5% in men (PP = 0.029), TNF-α by 41.4 vs 30.9%, NT-proBNP by 73.3 vs 46% (P = 0.002), Gal-3 by 82.3 vs 64.9% (P < 0.05). Group I also showed decrease of IL-10 by 34.2% (P < 0.05). Group dynamics of TIMP-1 was opposite: men showed tendency to reduction of TIMP-1 (P = 0.054), women showed increase of TIMP-1 (P < 0.05). Besides, men showed decrease of MMP-9 (P < 0.05) and ratio MMP-9/TIMP-4 (P < 0.05). Conclusion: The best response to CRT is associated with female gender explained by greater decrease of neurohormonal activation, systemic inflammation and fibrosis. The revealed opposite dynamics of TIMP-1 in the groups can demonstrate the existence of gender features of matrix metalloproteinase system activity and their tissue inhibitors.
Keywords: Cardiac Resynchronisation; Gender Differences; Therapy.
References
-
- Kuznetsov VA, Vinogradova TO, Enina TN, Kolunin GV, Kharats VE, Pavlov AV. et al. Impact of cardiac resynchronization therapy on survival in patients with ischemic and non-ischemic cardiomyopathy in clinical practice. Ther Arch. 2012;84(8):52–6. - PubMed
-
- Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA. et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC) Developed in collaboration with the European Heart Rhythm Association (EHRA) Eur Heart J. 2013;34(29):2281–329. doi: 10.1093/europace/eut206. - DOI - PubMed
-
- Rickard J, Michtalik H, Sharma R, Berger Z, Iyoha E, Green AR, et al. Use of Cardiac Resynchronization Therapy in the Medicare Population. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015. - PubMed
-
- Zusterzeel R, Spatz ES, Curtis J P, Sanders WE, Selzman KA, Pica IL. et al. Cardiac Resynchronization Therapy in Women Versus Men Observational Comparative Effectiveness Study From the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2015;8:4–11. doi: 10.1161/CIRCOUTCOMES.114.001548. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous